Its latest quarterly revenue reached 1.70M, representing a year-over-year increase of 137.00%, while its net profit experienced a year-over-year increase of 17.29%.
The current valuation score of ATAI Life Sciences NV is 7.36. Its current P/E ratio is -2.58, which is -55.47% below the recent high of -1.15 and -382.62% above the recent low of -12.46.
The current earnings forecast score of ATAI Life Sciences NV is 6.67. The average price target is 9.22, with a high of 16.00 and a low of 6.75.
The current price momentum score of ATAI Life Sciences NV is 1.89. Currently, the stock price is trading between the resistance level at 7.46 and the support level at 7.23, making it suitable for range-bound swing trading.
The latest institutional shareholding proportion is 19.93%, representing a quarter-over-quarter increase of 83.09%.
The current risk assessment score of ATAI Life Sciences NV is 4.51. The company's beta value is 1.60. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.